<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04489823</url>
  </required_header>
  <id_info>
    <org_study_id>ABT-CIP-10309</org_study_id>
    <nct_id>NCT04489823</nct_id>
  </id_info>
  <brief_title>PARADIGM: Amplatzer Valvular Plug for PVL Closure</brief_title>
  <acronym>PARADIGM</acronym>
  <official_title>PARADIGM PARAvalvular Leak Closure With the Amplatzer Valvular Plug occluDer for Interventional Transcatheter Closure for PVL With Surgical bioloGical and Mechanical Heart Valve</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Paradigm study is a prospective, multicenter, single arm study to demonstrate the safety&#xD;
      and effectiveness of the AVP III as a treatment for clinically significant PVLs following&#xD;
      surgical implant of a mechanical or biological heart valve implanted in the aortic or mitral&#xD;
      position.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PARADIGM is a prospective, international, multi-center, single arm study to demonstrate the&#xD;
      safety and effectiveness of the AVP III for percutaneous, transcatheter closure of PVLs&#xD;
      occurring after aortic or mitral valve replacement with a surgically-implanted mechanical or&#xD;
      bioprosthetic valve. The study will be conducted at up to 25 clinical sites in the US, EU and&#xD;
      Canada, where a total of 200 subjects with a clinically significant PVL will undergo an AVP&#xD;
      III implant procedure for PVL closure. Pre-procedural Baseline and follow-up assessments at&#xD;
      Discharge, 30 days, 6 months and 1 year will include echocardiography, physical examinations,&#xD;
      lab measurements and questionnaires to assess PVL severity, prosthetic valve function,&#xD;
      hemolytic anemia, heart failure symptoms, and quality of life. Adverse events will be&#xD;
      recorded throughout the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Paravalvular leak closure success rate (percent of subjects)</measure>
    <time_frame>30 Days</time_frame>
    <description>Defined as AVPIII placement in the intended location without interference with the prosthetic valve or intraprocedural mortality with at least a 2 severity-grade reduction in paravalvular regurgitation at exit from the procedure and freedom from unplanned AVPIII-related transcatheter or surgical reintervention through 30 days post-implant.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Paravalvular Aortic Regurgitation</condition>
  <arm_group>
    <arm_group_label>Paravalvular Leak Closure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Includes all eligible subjects who undergo an AVP III implant attempt for treatment of significant paravalvular leakage with an echocardiographic severity grade of moderate or higher. This is a single arm study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Amplatzer Valvular Plug III</intervention_name>
    <description>Transcatheter closure of a paravalvular leak using Amplatzer Valvular Plug III</description>
    <arm_group_label>Paravalvular Leak Closure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is implanted with a mechanical or biological surgical valve in the aortic or&#xD;
             mitral position&#xD;
&#xD;
          -  Note: Subjects in European countries can only be implanted with a mechanical valve in&#xD;
             the aortic or mitral position&#xD;
&#xD;
          -  Subject has a clinically significant paravalvular leak with a severity grade of&#xD;
             moderate or higher, associated with signs of heart failure and/or hemolysis&#xD;
             necessitating recurring blood transfusions.&#xD;
&#xD;
          -  Subject has one clinically significant PVL defect that can be closed with a single AVP&#xD;
             III as assessed pre-procedurally&#xD;
&#xD;
          -  Subject has provided written informed consent&#xD;
&#xD;
          -  Subject is ≥18 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has a rocking valve or extreme dehiscence of the prosthetic valve involving&#xD;
             more than 40% of the sewing ring&#xD;
&#xD;
          -  Subject's PVL(s) originates from a transcatheter aortic or mitral valve replacement,&#xD;
             or from rapid deployment or sutureless surgical replacement valves&#xD;
&#xD;
          -  Subject has a prosthetic aortic valve and prosthetic mitral valve which both have a&#xD;
             clinically significant paravalvular leak.&#xD;
&#xD;
          -  Subject who is hemodynamically unstable or who cannot undergo an elective procedure&#xD;
&#xD;
          -  Subject with active endocarditis or other active infection&#xD;
&#xD;
          -  Subject has within the last 6 months a previously documented intracardiac mass,&#xD;
             vegetation, tumor, or thrombus which would interfere with placement of the AVP III&#xD;
&#xD;
          -  Subject has inadequate vasculature for delivery of the AVP III&#xD;
&#xD;
          -  Subject has unsuitable anatomy for PVL closure using the AVP III (such as a PVL&#xD;
             associated with an abscess cavity or a pseudoaneurysmal sac) or anatomy where the AVP&#xD;
             III would interfere with other intracardiac or intravascular structures (such coronary&#xD;
             ostia)&#xD;
&#xD;
          -  Subjects who are unable to receive intraprocedural anticoagulant therapy&#xD;
&#xD;
          -  Pregnant or nursing subjects or subjects who plan pregnancy during the clinical&#xD;
             investigation follow-up period.&#xD;
&#xD;
          -  Presence of other anatomic or comorbid conditions, or other medical, social, or&#xD;
             psychological conditions that, in the investigator's opinion, could limit the&#xD;
             subject's ability to participate in the clinical investigation or to comply with&#xD;
             follow-up requirements, or impact the scientific soundness of the clinical&#xD;
             investigation results.&#xD;
&#xD;
          -  Life expectancy is less than 1 year in the opinion of the Investigator&#xD;
&#xD;
          -  Incapacitated individuals, defined as persons with mental illnesses or handicaps that&#xD;
             impair their ability to provide informed consent, or individuals without legal&#xD;
             authority to provide informed consent.&#xD;
&#xD;
          -  Individual who are currently participating in an investigational drug or device study&#xD;
             that has not reached the primary endpoint or that may confound the results of this&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Ruiz, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hackensack Meridian Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital - Univ. of Alabama at Birmingham (UAB)</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital/Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Memorial Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carilion Roanoke Memorial Hospital</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cardiologie de Quebec (Hôpital Laval)</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <zip>V6Z 2E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <state>Lombard</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <state>Utrecht</state>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gornoslaskie Centrum Medyczne im.prof. Leszka Gieca</name>
      <address>
        <city>Katowice</city>
        <state>Silesia</state>
        <zip>40-635</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edinburgh Heart Centre</name>
      <address>
        <city>Edinburgh</city>
        <state>Lothian</state>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Sussex County Hospital</name>
      <address>
        <city>Brighton</city>
        <state>Soeast</state>
        <zip>BN25BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 10, 2020</study_first_submitted>
  <study_first_submitted_qc>July 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2020</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

